Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Millennium Management LLC

Millennium Management LLC boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 575.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 3,118,035 shares of the company's stock after purchasing an additional 2,656,173 shares during the period. Millennium Management LLC owned approximately 4.56% of Replimune Group worth $28,062,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of REPL. Quest Partners LLC lifted its stake in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company's stock worth $122,000 after acquiring an additional 3,150 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock worth $45,000 after acquiring an additional 4,946 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Replimune Group by 72.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company's stock worth $96,000 after acquiring an additional 4,975 shares during the period. Los Angeles Capital Management LLC lifted its stake in shares of Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company's stock worth $646,000 after acquiring an additional 5,410 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Replimune Group by 7.2% in the 2nd quarter. Rhumbline Advisers now owns 84,923 shares of the company's stock worth $764,000 after acquiring an additional 5,732 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 20.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 24th. Barclays raised their price objective on shares of Replimune Group from $13.00 to $17.00 and gave the company an "overweight" rating in a research note on Friday, June 7th. HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Monday, September 16th. Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Replimune Group has an average rating of "Buy" and an average price target of $16.80.

Replimune Group Price Performance

REPL traded down $0.13 during midday trading on Friday, reaching $11.56. 418,506 shares of the company's stock were exchanged, compared to its average volume of 1,123,330. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The stock has a market capitalization of $789.78 million, a PE ratio of -3.61 and a beta of 1.22. The business's 50-day moving average price is $10.46 and its 200 day moving average price is $8.59. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $16.70.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.88) by $0.10. As a group, equities analysts anticipate that Replimune Group, Inc. will post -3.11 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.